The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up

Hallissey, M. T.; Dunn, Janet A.; Ward, LC; Allum, William; Group, British Stomach Cancer

doi:10.1016/s0140-6736(94)92464-3

Cited by 262 publications

(102 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several recent meta-analyses have indicated that, even with pooled data, postoperative adjuvant systemic therapy produces only a modest improvement in survival (Earle and Maroun, 1999;Mari et al, 2000;Janunger et al, 2001). Likewise, adjuvant radiotherapy alone has also failed to demonstrate any survival benefit (Hallissey et al, 1994). Recognition of the high locoregional failure rates following surgery has resulted in four separate randomised trials evaluating the role of extended lymph node dissection (Robertson et al, 1994;Dent et al, 1988;Bonenkamp et al, 1999;Cuschieri et al, 1999).…”

Section: Discussionmentioning

confidence: 99%

Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation

et al. 2003

View full text Add to dashboard Cite

Chemoradiation is now used more commonly for gastric cancer following publication of the US Intergroup trial results that demonstrate an advantage to adjuvant postoperative chemoradiotherapy. However, there remain concerns regarding the toxicity of this treatment, the optimal chemotherapy regimen and the optimal method of radiotherapy delivery. In this prospective study, we evaluated the toxicity and feasibility of an alternative chemoradiation regimen to that used in the Intergroup trial. A total of 26 patients with adenocarcinoma of the stomach were treated with 3D-conformal radiation therapy to a dose of 45 Gy in 25 fractions with concurrent continuous infusional 5-fluorouracil (5-FU). The majority of patients received epirubicin, cisplatin and 5-FU (ECF) as the systemic component given before and after concurrent chemoradiation. The overall rates of observed grade 3 and 4 toxicities were 38 and 15%, respectively. GIT grade 3 toxicity was observed in 19% of patients, while haematologic grade 3 and 4 toxicities were observed in 23%. Our results suggest that this adjuvant regimen can be delivered safely and with acceptable toxicity. This regimen forms the basis of several new studies being developed for postoperative adjuvant therapy of gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation

et al. 2003

View full text Add to dashboard Cite

show abstract

“…se exploró la posibilidad de aumentar la supervivencia de pacientes operados con intención curativa mediante el tratamiento combinado de quimiorradioterapia (QT/RT) postoperatoria, basados en estudios publicados previamente que mostraron un potencial beneficio de la QT/RT en la supervivencia libre de enfermedad de pacientes con cáncer gástrico de mal pronóstico 7-9 y considerando que ni la quimioterapia (QT) sola, ni la radioterapia (RT) sola habían podido demostrar beneficio 10 . Inicialmente se optó por un esquema de RT sobre abdomen total, basado en la observación de una alta tasa de recurrencias peritoneales 11 , en los datos que mostraban que la RT en dosis bajas era capaz de erradicar la enfermedad subclínica 12 y extrapolando la experiencia positiva de otras patologías 13 .…”

Section: N V E S T I G a C I ó Nunclassified

Quimiorradioterapia adyuvante en el cáncer gástrico resecado con intención curativa: Análisis de supervivencia y toxicidad de pacientes tratados entre 1995 y 2003 en el Instituto Nacional del Cáncer, Chile

Müller¹,

Balbontín²,

Cárcamo³

et al. 2009

Rev. méd. Chile

View full text Add to dashboard Cite

“…In spite of the improvement in surgical treatment and chemotherapy, the prognosis in this disease is still poor owing to local recurrence or metastasis (Baba et al, Bonenkamp et al, 1995;Hallissey et al, 1994;Nakazato et al, 1994).…”

mentioning

confidence: 99%

Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer

Hirono

Fushida²,

Yonemura³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary Up-regulation of autocrine motility factor receptor (AMF-R) expression has been shown to be associated with invasion and metastasis of experimental tumour systems and human neoplasms. Monoclonal antibodies against AMF-R (gp78) were used to stain 221 primary gastric cancer specimens, and level of expression was examined in relation to pathological stage and prognostic values. In 125 out of 221 (56.6%) patients, gp78 was detected. Expression of gp78 was associated with macroscopic type, lymphatic and venous invasions, and lymph node and peritoneal metastasis. The level of gp78 expression in the cancer specimens was associated with histopathological stage and grade of tumour penetration. Positive gp78 expression was significantly associated with poor prognosis (P<0.001). This significant relationship remained among patients in stages II and III. The results suggest that gp78 expression could be used as a prognostic marker in gastric cancer patients.Keywords: gastric cancer; autocrine motility factor receptor; cell motility; invasion; metastasis The incidence of gastric carcinoma is the highest of all carcinomas, and it is the leading cause of death from cancer in Japan. In spite of the improvement in surgical treatment and chemotherapy, the prognosis in this disease is still poor owing to local recurrence or metastasis (Baba et al., 1995; Bonenkamp et al., 1995;Hallissey et al., 1994;Nakazato et al., 1994).Many investigators study the mechanism of tumour cell invasion and metastasis to better understand local recurrence and metastasis (Nekarda et al., 1994;Nomura et al., 1995; Sato et al., 1994; Yonemura et al., 1995). Among the various steps of invasion or metastasis of the cancer cell, cell motility is one of the important factors that promotes cancer progression (Fidler, 1990;Hart et al., 1989;Liotta et al., 1986;Nabi et al., 1991). However, the relationship between gastric cancer stages and cell motility-regulated factors has not been reported. Thus, it is of obvious interest to study such parameters in order to obtain an insight into the biological behaviour of gastric cancers.Autocrine motility factor (AMF) is a cytokine that is produced and secreted by cancer cells and that stimulates both random and directed cell migration through binding to its receptor, a 78 kDa cell surface glycoprotein (gp78, AMF receptor) (Liotta et al., 1986;Nabi et al., 1990Nabi et al., , 1991Silletti et al., 1991). Recently, a molecular cloning of AMF receptor (AMF-R) was reported (Watanabe et al., 1991a). Expression of this receptor relates to cell motility-regulating effects and also may play an important role in tumour cell invasion or metastasis (Nabi et al., 1992;Watanabe et al., 1991b). Recent studies have demonstrated that increased expression of gp78 is correlated with a high incidence of recurrence and decreased survival of patients with colorectal cancer, bladder cancer and oesophageal cancer (Nakamori et al., 1994;Otto et al., 1994;Maruyama et al., 1995).Here, we studied the expression of gp78 in specimens from ...

show abstract

The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up

Cited by 262 publications

References 18 publications

Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation

Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation

Quimiorradioterapia adyuvante en el cáncer gástrico resecado con intención curativa: Análisis de supervivencia y toxicidad de pacientes tratados entre 1995 y 2003 en el Instituto Nacional del Cáncer, Chile

Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer

Contact Info

Product

Resources

About